ABSTRACT
Objective: To explore the values of fecal mircoRNA (miRNA, miR) in diagnosis and prognostic evaluation of colorectal cancer. Methods: Fifty colorectal cancer patients and fifty healthy controls were included in this study. The contents of fecal miR-141, miR-17-3p and miR-92a-3p in all subjects were detected by real-time fluorescent quantitative PCR before operation. The differences of the three mircoRNA levels between the two groups were analyzed. Then the diagnostic efficiency of the three miRNAs for colorectal cancer was assessed by using receiver operating characteristic (ROC) curve. Furthermore, the differences of fecal miR-141 and miR-92a-3p levels in colorectal cancer patients between preoperation and postoperation (6 months after operation) were analyzed. The recurrence of colorectal cancer patients in 12 months after operation was followed up, then the differences between postoperative and preoperative fecal miR-141 contents in patients with and without recurrence were analyzed. Results: The levels of fecal miR-141 and miR-92a-3p in colorectal cancer group were significantly higher than those in the control group (both P < 0.01). There was no significant difference in fecal miR-17-3p level between the two groups (P = 0.30). ROC curve analysis showed that the areas under the curve (AUC) of fecal miR-141 and miR-92a-3p were 0.874 [95% confidence interval (CI): 0.803-0.946] and 0.789 (95% CI : 0.703-0.876), respectively. The level of fecal miR-141 in colorectal cancer patients 6 months after operation was significantly lower than that before operation (P < 0.01), while there was no significantly difference between postoperative and preoperative fecal miR-92a-3p levels (P = 0.08). The difference between postoperative and preoperative fecal miR-141 contents in 4 patients with recurrence was significantly less than that in 46 patients without recurrence (P < 0.05). Conclusion: The fecal miR-141 and miR-92a-3p were highly expressed in patients with colorectal cancer, so that they may be used as the non-invasive biomarkers for the auxiliary diagnosis of colorectal cancer. In particular, the fecal miR-141 may have a certain value in evaluating the surgical outcomes and prognosis of colorectal cancer, as well as monitoring the postoperative recurrence.
ABSTRACT
Objective To explore the expression and diagnostic value of serum microRNA-574-3p (miR-574-3p) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).Methods A total of 90 patients with HBV-related HCC,40 patients with HBV-related liver cirrhosis (LC) and 50 healthy controls were recruited.The expression levels of serum miR-574-3p,α-fetoprotein (AFP) and α-Lfucosidase (AFU) of all subjects were determined.The difference of serum miR-574-3p level between groups was compared.The relation between serum miR-574-3p level of HCC patients and its clinical pathological characteristics was analyzed.The t-test was performed.The relationship between serum miR-574-3p level of HCC patients and AFP,AFU was analyzed by Spearman correlation analysis.The diagnostic efficacy of them as diagnostic markers was evaluated by receiver operating characteristic curves (ROC) and the area under the curve (AUC)(95％ CI (confidence interval)).Results The relative quantity expression of serum miR-574-3p of HCC group,LC group and healthy group was 2.152(1.654,3.061),1.292 (0.984,1.666) and 1.018 (0.750,1.726),respectively.The expression level of serum miR-574-3p of HCC group was significantly higher than those of LC group and healthy control group,and the differences were statistically significant (t=2.726 and 2.845,both P＜0.01).The expression level of serum miR-574-3p of HCC patients was significantly different in tumors with different degree of differentiation (t=2.262,P=0.039),different stage (t=2.354,P=0.025) and different HBV DNA concentrations (t=2.771,P＜0.01).There was no correlation between serum miR-574-3p level and AFP (r2 =0.076,P=0.505),AFU (r2 =0.082,P=0.422) in HCC patients.When compared HCC group with LC group,AUC of serum miR-574-3p of was 0.823 and 95％ CI was 0.750 to 0.897.When compared HCC group with healthy control group,AUC of serum miR-574-3p was 0.840 and 95％CI was 0.769 to 0.910.Conclusions The expression level of serum miR-574-3p of HCC patients is significantly higher than those of LC patients and healthy controls.Serum miR-574-3p may be an important biomarker in the diagnosis of HCC.